NONALCOHOLIC FATTY LIVER DISEASE AND CARDIOVASCULAR RISK: INFLUENCE OF FEMALE SEX


Cite item

Full Text

Abstract

The article considers the non-alcoholic fatty liver disease (NAFLD), one of the components of metabolic syndrome according to modern concepts. It is emphasized that NAFLD is associated with cardiovascular diseases (CVD) and apparently predicts their development. The article discusses the influence of female sex on the incidence of NAFLD; it is noted that risk of cardiovascular diseases increases dramatically against the background of menopause or gynecological pathology. Essential phospholipids (EFL) are effective means for the treatment of NAFLD. Preparations of EFL (Essentiale forte, Essentiale N) competitively replace endogenous phospholipid phosphatidylcholine of cell membranes and restore damaged membrane structures of cells through the incorporation of EFL molecules in membrane and filling gaps in membrane, stimulate the synthesis of endogenous phospholipids. In the treatment of patients with NAFLD and CVD, the benefits of use of EFL are improvement of receptor function, including insulin receptors, and normalization of lipid metabolism.

References

  1. Bedogni G, Miglioli L, Masutti F, et al. Prevalence and risk factors for non-alcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005;42:44-52.
  2. Nomura H, Kashiwaqi S, Hayashi J, et al. Prevalence of fatty liver in a general population of Okinawa Japan. Jpn J Med 1988;27:142-49.
  3. Ramilli S, Pretolani S, Muscari A, et al. Carotid lesions in outpatients with nonalcoholic fatty liver disease. World J Gastroenterol 2009;15(38) 4770-74.
  4. Targher G, Bertolini L, Rodella S, et al. Nonalcoholic Fatty Liver Disease Is Independently Associated With an Increased Incidence of Cardiovascular Events in Type 2 Diabetic Patients. Diabetes Care 2007;30(8):2119-21.
  5. Hickman I, Sullivan C, Flight S, et al. Altered clot kinetics in patients with non-alcoholic fatty liver disease. Annals of Hepatology 2009;8(4):331-38.
  6. Hamaguchi M, Kojima T, Takeda N, et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol 2007;13(10):1579-84.
  7. Clark JM. The epidemiology of non alcoholic fatty liver disease in adults. J Clin Gastroenterol 2006;40(1):5-10.
  8. Болезни печени и желчевыводящих путей: Руководство для врачей. / Под редакцией Ивашкина В.Т. 2-е изд. М., 2005. C. 536.
  9. Bacon BR, Farahvash MJ, Janney CG, et al. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994;107:1103-09.
  10. Amarapurkar D, Kamani P, Patel N, et al. Prevalence of non-alcoholic fatty liver disease: population based study. Annals of Hepatology 2007;6(3):161-63.
  11. Rocha R, Cotrim НР, Bitencourt A, et al. Nonalcoholic fatty liver disease in asymptomatic Brazilian adolescents. World J Gastroenterol 2009;15(4):473-77.
  12. Tominaga K, Fujimoto E, Suzuki K, et al. Prevalence of non-alcoholic fatty liver disease in children and relationship to metabolic syndrome, insulin resistance, and waist circumference. Environ Health Prev Med 2009;14(2):142-49.
  13. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288(3):321-33.
  14. Subbiah MT. Estrogen replacement therapy and cardioprotection: mechanisms and controversies. Braz J Med Biol Res 2002;35:271-76.
  15. Rossi R, Origliani G, Modena MG. Transdermal 17-в-estradiol and risk of developing type 2 diabetes in a population of healthy, nonobese postmenopausal women. Diabetes Care 2004;27:645-49.
  16. Barrett-Connor E, Grady D, Stefanick ML. The rise and fall of menopausal hormone therapy. Annu Rev Public Health 2005;26:115-40.
  17. Shimizu I. Impact of oestrogens on the progression of liver disease. Liver Int 2003;23:63-69.
  18. Clark JM, Bracanti FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002;122:1649-57.
  19. Ameen C, Oscarsson J. Sex difference in hepatic microsomal triglyceride transfer protein expression is determined by the growth hormone secretory pattern in the rat. Endocrinology 2003;144:3914-21.
  20. Lonardo A, Carani C, Carulli N, et al. EndocrineNAFLD a hormonocentric perspective of nonalcoholic fatty liver disease pathogenesis. J Hepatol 2006;44:1196-207.
  21. Cerda C, Perez-Ayuso R, Riquelme A. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. J of Hepatol 2007;47:412-17.
  22. Ludwig J, Viggiano TR, McGill DB, et al. Nonalcoholic steatohepatitis. Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434-38.
  23. Angulo P, Keach JC, Batts KP, et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999;30(6):1356-62.
  24. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001;121(1):91-100.
  25. Ratziu V, Giral P, Charlotte F. liver fibrosis in overweight patients. Gastroenterology 2000;118(1):1117-23.
  26. Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44:865-73.
  27. Huang MA, Greenson JK, Chao C, et al. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: A pilot study. Am J Gastroenterol 2005;100:1072-81.
  28. Буеверов А.О., Ешану В.С., Маевская М.В., Ивашкин В.Т. Эссенциальные фосфолипиды в комплексной терапии стеатогепатита смешанного генеза // Клин. перспект. гастроэнтерол. и гепатол. 2008. № 1. С. 17-22.
  29. Драпкина О.М., Корнеева О.Н., Ивашкин В.Т. Терапия неалкогольного стеатогепатита при метаболическом синдроме: фокус на эссенциальные фосфолипиды // Лечащий врач. 2010. № 2. С. 18-24.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies